Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06481098 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.
A Phase 1 study of Obesity, sponsored by Hanmi Pharmaceutical Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT06481098: Completed Phase 1 study of Obesity, sponsored by Hanmi Pharmaceutical Company Limited.
NCT06481098 is a Phase 1 study of Obesity that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 74 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06481098, a Phase 1 study of Obesity, has completed, sponsored by Hanmi Pharmaceutical Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
This Study is a Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects.
Primary Outcome
Number of participants with treatment-emergent adverse events (TEAEs) after a single subcutaneous dose
Conditions Studied
Interventions
- DRUG HM15275
- DRUG Placebo of HM15275
Study Locations (1)
California
- ProSciento, Inc. - Chula Vista
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2024-05-28 |
| Est. Completion | 2025-05-02 |
| Phase | Phase 1 |
What the finished NCT06481098 record still lists
NCT06481098 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which HM15275 is the first listed.
NCT06481098 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06481098 about?
NCT06481098 is a clinical study titled "A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.". This Study is a Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects.
What is the current status of trial NCT06481098?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2024-05-28. Estimated completion is 2025-05-02.
What conditions does trial NCT06481098 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06481098?
The interventions under investigation include: HM15275 (DRUG), Placebo of HM15275 (DRUG).
Who is sponsoring clinical trial NCT06481098?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06481098 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06481098's enrollment target sits among peer trials
74 574th of 1053 higher than 479 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI